
|Videos|October 7, 2017
CD101: A New Long-Acting Echinocandin
Author(s)Contagion® Editorial Staff
David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.
Advertisement
David Andes, MD, professor and chief of infectious disease at the University of Wisconsin, shares the half-life and dosing intervals for a new long-acting echinocandin.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
The Latest on the Cyclosporiasis Outbreak: An FDA False Positive Test, and What Treatment Looks Like
2
Researching Repurposed Medications for Long COVID
3
Cyclosporiasis Case Count Tops 7000 as Lettuce Probe Continues
4
Once-Weekly Islatravir/Lenacapavir Meets Phase 3 Primary End Point
5




























































































































































